• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

疾病缓解成为溃疡性结肠炎的新结局:系统评价和专家共识。

Disease Clearance as a New Outcome in Ulcerative Colitis: a Systematic Review and Expert Consensus.

机构信息

Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and Vita-Salute San Raffaele University, Milan, Italy.

Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.

出版信息

Inflamm Bowel Dis. 2024 Jun 3;30(6):1009-1017. doi: 10.1093/ibd/izad159.

DOI:10.1093/ibd/izad159
PMID:37549104
Abstract

The concept of disease clearance has been proposed as a potential target in ulcerative colitis (UC). We conducted a systematic review to investigate the role of disease clearance, defined as a composite outcome including simultaneous clinical, endoscopic, and histologic remission of disease in the management of patients with UC. Based on the literature data, statements regarding disease clearance were developed and voted on by the members of the International Organization for the Study of Inflammatory Bowel Diseases (IOIBD) according to a Delphi methodology. A definition of disease clearance was proposed to standardize its use in clinical practice and clinical trials and to provide practical recommendations for its implementation as a therapeutic target in UC.

摘要

疾病缓解的概念已被提出作为溃疡性结肠炎(UC)的一个潜在目标。我们进行了一项系统综述,旨在研究疾病缓解(定义为同时达到临床、内镜和组织学疾病缓解的复合结局)在 UC 患者管理中的作用。根据文献数据,国际炎症性肠病研究组织(IOIBD)的成员采用德尔菲法制定并投票表决了关于疾病缓解的声明。提出了疾病缓解的定义,以规范其在临床实践和临床试验中的应用,并为将其作为 UC 的治疗目标提供实施的实用建议。

相似文献

1
Disease Clearance as a New Outcome in Ulcerative Colitis: a Systematic Review and Expert Consensus.疾病缓解成为溃疡性结肠炎的新结局:系统评价和专家共识。
Inflamm Bowel Dis. 2024 Jun 3;30(6):1009-1017. doi: 10.1093/ibd/izad159.
2
Practical management of mild-to-moderate ulcerative colitis: an international expert consensus.轻度至中度溃疡性结肠炎的实用管理:国际专家共识。
Expert Rev Gastroenterol Hepatol. 2024 Aug;18(8):421-430. doi: 10.1080/17474124.2024.2397650. Epub 2024 Sep 3.
3
Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus.溃疡性结肠炎临床试验中内镜反应和缓解的定义:一项国际共识
Aliment Pharmacol Ther. 2017 Mar;45(6):801-813. doi: 10.1111/apt.13948. Epub 2017 Jan 23.
4
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD.STRIDE-II:炎症性肠病(STRIDE)国际研究组织(IOIBD)治疗靶点选择更新:确定炎症性肠病靶向治疗策略的治疗目标。
Gastroenterology. 2021 Apr;160(5):1570-1583. doi: 10.1053/j.gastro.2020.12.031. Epub 2021 Feb 19.
5
Selecting End Points for Disease-Modification Trials in Inflammatory Bowel Disease: the SPIRIT Consensus From the IOIBD.选择炎症性肠病的疾病修正试验终点:IOIBD 的 SPIRIT 共识。
Gastroenterology. 2021 Apr;160(5):1452-1460.e21. doi: 10.1053/j.gastro.2020.10.065. Epub 2021 Jan 6.
6
Histologic assessments in ulcerative colitis: the evidence behind a new endpoint in clinical trials.溃疡性结肠炎的组织学评估:临床试验中新终点的证据。
Expert Rev Gastroenterol Hepatol. 2024 Jan-Feb;18(1-3):73-87. doi: 10.1080/17474124.2024.2326838. Epub 2024 Mar 21.
7
Defining Comprehensive Disease Control for Use as a Treatment Target for Ulcerative Colitis in Clinical Practice: International Delphi Consensus Recommendations.定义综合疾病控制作为临床实践中溃疡性结肠炎的治疗目标:国际德尔菲共识推荐
J Crohns Colitis. 2024 Jan 27;18(1):91-105. doi: 10.1093/ecco-jcc/jjad130.
8
Endoscopic mucosal healing and histologic remission in ulcerative colitis: a systematic literature review of clinical, quality-of-life and economic outcomes.溃疡性结肠炎的内镜下黏膜愈合和组织学缓解:对临床、生活质量及经济结局的系统文献综述
Curr Med Res Opin. 2022 Sep;38(9):1531-1541. doi: 10.1080/03007995.2022.2081453. Epub 2022 Jun 11.
9
Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus.非住院溃疡性结肠炎的医学管理临床实践指南:多伦多共识。
Gastroenterology. 2015 May;148(5):1035-1058.e3. doi: 10.1053/j.gastro.2015.03.001. Epub 2015 Mar 4.
10
An International Consensus to Standardize Integration of Histopathology in Ulcerative Colitis Clinical Trials.溃疡性结肠炎临床试验中组织病理学整合的国际共识标准化
Gastroenterology. 2021 Jun;160(7):2291-2302. doi: 10.1053/j.gastro.2021.02.035. Epub 2021 Feb 19.

引用本文的文献

1
Asia Pacific association of gastroenterology consensus statements on histopathological evaluation of inflammatory bowel diseases.亚太胃肠病学协会关于炎症性肠病组织病理学评估的共识声明
Therap Adv Gastroenterol. 2025 Aug 19;18:17562848251363703. doi: 10.1177/17562848251363703. eCollection 2025.
2
Defining partial response in inflammatory bowel disease: a Delphi consensus and economic evaluation.炎症性肠病中部分缓解的定义:德尔菲共识与经济学评估
Therap Adv Gastroenterol. 2025 Aug 18;18:17562848251360907. doi: 10.1177/17562848251360907. eCollection 2025.
3
Clinical Trial: Association Between Early Disease Clearance and Long-Term Outcomes-4-Year Results From the Phase 3 UNIFI Study of Ustekinumab in Ulcerative Colitis.
临床试验:早期疾病清除与长期预后的关联——优特克单抗治疗溃疡性结肠炎的3期UNIFI研究的4年结果
Aliment Pharmacol Ther. 2025 Sep;62(5):483-492. doi: 10.1111/apt.70264. Epub 2025 Jul 16.
4
Disease Clearance in Ulcerative Colitis: A Narrative Review.溃疡性结肠炎的疾病清除:一项叙述性综述
United European Gastroenterol J. 2025 Jul;13(6):902-910. doi: 10.1002/ueg2.12714. Epub 2025 Apr 16.
5
Novel outcomes in inflammatory bowel disease.炎症性肠病的新成果。
J Crohns Colitis. 2025 Apr 4;19(4). doi: 10.1093/ecco-jcc/jjaf040.
6
Dual Biologic Therapy Induces Remission in Refractory Crohn's Disease With Vedolizumab and Ustekinumab.维多珠单抗和优特克单抗联合生物疗法可诱导难治性克罗恩病缓解。
Crohns Colitis 360. 2024 Dec 17;7(1):otae080. doi: 10.1093/crocol/otae080. eCollection 2025 Jan.
7
Advancing Therapeutic Targets in IBD: Emerging Goals and Precision Medicine Approaches.炎症性肠病治疗靶点的进展:新出现的目标与精准医学方法
Pharmaceuticals (Basel). 2025 Jan 10;18(1):78. doi: 10.3390/ph18010078.
8
Raising the bar in ulcerative colitis management.提高溃疡性结肠炎的治疗标准。
Therap Adv Gastroenterol. 2024 Nov 24;17:17562848241273066. doi: 10.1177/17562848241273066. eCollection 2024.
9
Defining mucosal healing in randomized controlled trials of inflammatory bowel disease: A systematic review and future perspective.在炎症性肠病的随机对照试验中定义黏膜愈合:系统评价和未来展望。
United European Gastroenterol J. 2024 Nov;12(9):1266-1279. doi: 10.1002/ueg2.12671. Epub 2024 Oct 5.
10
Deep mucosal healing in ulcerative colitis: how deep is better?溃疡性结肠炎的深度黏膜愈合:多深才算更好?
Front Med (Lausanne). 2024 Aug 2;11:1429427. doi: 10.3389/fmed.2024.1429427. eCollection 2024.